Historical Valuation
MIRA Pharmaceuticals Inc (MIRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.83. The fair price of MIRA Pharmaceuticals Inc (MIRA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.48
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
MIRA Pharmaceuticals Inc (MIRA) has a current Price-to-Book (P/B) ratio of 7.80. Compared to its 3-year average P/B ratio of 14.59 , the current P/B ratio is approximately -46.53% higher. Relative to its 5-year average P/B ratio of 14.59, the current P/B ratio is about -46.53% higher. MIRA Pharmaceuticals Inc (MIRA) has a Forward Free Cash Flow (FCF) yield of approximately -8.54%. Compared to its 3-year average FCF yield of -23.42%, the current FCF yield is approximately -63.52% lower. Relative to its 5-year average FCF yield of -23.42% , the current FCF yield is about -63.52% lower.
P/B
Median3y
14.59
Median5y
14.59
FCF Yield
Median3y
-23.42
Median5y
-23.42
Competitors Valuation Multiple
AI Analysis for MIRA
The average P/S ratio for MIRA competitors is 101.07, providing a benchmark for relative valuation. MIRA Pharmaceuticals Inc Corp (MIRA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MIRA
1Y
3Y
5Y
Market capitalization of MIRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MIRA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MIRA currently overvalued or undervalued?
MIRA Pharmaceuticals Inc (MIRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.83. The fair price of MIRA Pharmaceuticals Inc (MIRA) is between to according to relative valuation methord.
What is MIRA Pharmaceuticals Inc (MIRA) fair value?
MIRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of MIRA Pharmaceuticals Inc (MIRA) is between to according to relative valuation methord.
How does MIRA's valuation metrics compare to the industry average?
The average P/S ratio for MIRA's competitors is 101.07, providing a benchmark for relative valuation. MIRA Pharmaceuticals Inc Corp (MIRA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for MIRA Pharmaceuticals Inc (MIRA) as of Jan 10 2026?
As of Jan 10 2026, MIRA Pharmaceuticals Inc (MIRA) has a P/B ratio of 7.80. This indicates that the market values MIRA at 7.80 times its book value.
What is the current FCF Yield for MIRA Pharmaceuticals Inc (MIRA) as of Jan 10 2026?
As of Jan 10 2026, MIRA Pharmaceuticals Inc (MIRA) has a FCF Yield of -8.54%. This means that for every dollar of MIRA Pharmaceuticals Inc’s market capitalization, the company generates -8.54 cents in free cash flow.
What is the current Forward P/E ratio for MIRA Pharmaceuticals Inc (MIRA) as of Jan 10 2026?
As of Jan 10 2026, MIRA Pharmaceuticals Inc (MIRA) has a Forward P/E ratio of -2.90. This means the market is willing to pay $-2.90 for every dollar of MIRA Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for MIRA Pharmaceuticals Inc (MIRA) as of Jan 10 2026?
As of Jan 10 2026, MIRA Pharmaceuticals Inc (MIRA) has a Forward P/S ratio of 0.00. This means the market is valuing MIRA at $0.00 for every dollar of expected revenue over the next 12 months.